Wall Street expects a year-over-year increase in earnings on higher revenues when Blueprint Medicines (BPMC) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 15, 2024, might help the stock move higher if these key numbers are bet ...

CAMBRIDGE, Mass., Feb. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 1,717 shares of its common stock and an aggregate of 858 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity award ...

Blueprint Medicines Corporation (BPMC) is focused on developing transformational precision medicines to address genomically defined cancers and rare diseases.The company’s lead drug, Ayvakit/Ayvakyt (avapritinib), a kinase inhibitor, is approved for three rare cancer indications, both in the United States and the EU. The drug is approved for treating adults with PDGFRA Exon 18 mutant gastrointestinal stromal tumors, adults with advanced systemic mastocytosis and adults with indolent systemic mastocytosis (S ...

Blueprint Medicines (BPMC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual i ...

Third Quarter 2023 Financial Results Not for promotional use Agenda AYVAKIT PERFORMANCE Q3 2023 FINANCIAL PERFORMANCE Kate Haviland Chief Executive Officer Christy Rossi Chief Operating Officer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidate ...

Financial Data and Key Metrics Changes - The company reported total revenues of $56.6 million for Q3 2023, including $54.2 million in net product revenues from AYVAKIT, marking a 90% growth compared to the previous year [24][40][31] - The number of patients on AYVAKIT therapy in the US increased to approximately 800, a significant rise of over 200 patients since the last quarter [10][24][75] Business Line Data and Key Metrics Changes - AYVAKIT's net product revenues nearly doubled from the same time last year, reflecting strong demand and effective market penetration [31][40] - The breadth of prescribing has expanded rapidly across various specialties, with allergists accounting for a significant portion of new systemic mastocytosis (SM) starts in Q3 [12][31] Market Data and Key Metrics Changes - The company has seen a substantial increase in the diagnosed prevalence of systemic mastocytosis, with estimates rising from about 11,000 patients in 2019 to over 17,000 or 18,000 currently [70][72] - Approximately 95% of lives are now covered by payer policies for AYVAKIT, indicating strong market access [14][31] Company Strategy and Development Direction - The core strategy focuses on extending leadership in systemic mastocytosis and expanding into other mast cell disorders, leveraging scientific innovation and commercial execution [16][20] - The company aims to broaden the adoption of AYVAKIT among a wider range of patients and expand into additional geographies, including anticipated approval in the EU [33][104] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable revenue growth and a path to profitability, with expectations of a significant decrease in cash burn in 2024 [29][62] - The company is committed to maintaining a strong balance sheet while managing expenses effectively as revenues ramp up [61][63] Other Important Information - The company plans to provide 2024 revenue guidance inclusive of AYVAKIT on the Q4 earnings call, indicating a strong trajectory for the product [41][98] - AYVAKIT is positioned as a cornerstone of the company's franchise, with ongoing efforts to enhance its market presence and patient access [9][37] Q&A Session Summary Question: What are the portfolio goals and strategy updates for 2024? - Management indicated a focus on leveraging expertise in KIT biology and building relationships in the allergy immunology space, with a commitment to high standards for investment in long-term value [45][46] Question: Are there any insights into the patient retention rate? - Management noted that it is still early to provide specific retention rates, but there is confidence in continued strong and steady growth [128][98] Question: How is the company addressing the increase in diagnosis rates? - The company has seen a significant increase in diagnosed patients, attributing this to both the development of AYVAKIT and ongoing commercialization efforts [70][72] Question: What are the expectations for elenestinib's development after ASH? - Management views ASH as a critical step in demonstrating elenestinib's safety and activity, with plans to develop a robust data set for this next-generation therapy [85][109] Question: How does the company view the competitive landscape for AYVAKIT? - The company acknowledges that AYVAKIT has set a high bar for any new therapy, emphasizing the need for new agents to demonstrate broad symptom impact and a favorable safety profile [106][58]

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...

9 Second Quarter 2023 Financial Results AUGUST 2, 2023 INTRODUCTION AYVAKIT PERFORMANCE KEY PORTFOLIO MILESTONES Q2 2023 FINANCIAL PERFORMANCE Not for promotional use Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candi dates ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Jenna Cohen - VP, IR Kate Haviland - CEO Philina Lee - CCO Fouad Namouni - President, R&D Mike Landsittel - CFO Christy Rossi - COO Becker Hewes - CMO Conference Call Participants Brad Canino - Stifel Dane Leone - Raymond James Reni Benjamin - JMP Securities Eun Yang - Jefferies Marc Frahm - TD Cowen Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Partners Ami Fadia - Ne ...

Table of Contents The Company evaluated the Zai Lab agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the Zai Lab agreement is a collaborative agreement under ASC 808 as both parties are active participants in the clinical trials and are exposed to significant risks and rewards of those activities under the Zai Lab agreement. The Company determined that the Zai Lab agreement contained two material components: (i) licenses granted to Zai Lab ...